EWG maintains that “the result of the election has no effect whatsoever on the need for cosmetics reform,” but it remains to be seen how legislative proposals for increased oversight would be received by the president-elect, who has outlined plans for dramatically cutting perceived overregulation. Meanwhile, new leadership is likely to be appointed at FDA, and hopes dwindle regarding the Trans-Pacific Partnership.
Donald Trump’s surprise victory Nov. 9 over Hillary Clinton in an historic presidential race has given rise to numerous questions about the election’s ramifications and the course US policy will take under his lead.
Immigration, foreign policy, Obamacare and tax reform are among issues that are top of mind for many as the political...
Create an account to read this article
Already a subscriber?
OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.
As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.
Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.
What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.
OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.
As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.
Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.
